Sydney, Australia 18 March 2016 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, has been awarded the maximum amount of Accelerating Commercialisation grant funding. This grant is part of the Australian Government’s Entrepreneurs’ Programme and will be used to commercialise Clarity’s novel radiopharmaceutical for treating cancer, SARTATE™. The grant, valued…
Sydney, Australia 18 December 2015 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, has been awarded a Research Connections Grant under the Entrepreneurs’ Programme. The grant, valued at $50,000, will go toward funding the employment of Australian scientist Charmaine Jeffery as Preclinical Development Manager, who will be responsible for conducting…
Sydney, Australia 16 October 2015 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, has been awarded a Business Growth Grant under the Entrepreneurs’ Programme. The grant, valued at $20,000, will help fund Clarity’s drug development pipeline project plan. The grant will be used to provide funding to engage Dr Ellen…
“Imaging technology is guiding cutting edge drug development.” Clarity Pharmaceuticals was featured in dealflow, the publication for the Entrepreneurs’ Programme which profiles some of the best performing and highest potential businesses that have received commercialisation support from the Australian Government. “Today’s biopharmaceutical companies are under pressure to meet the demand for more personalised therapies, where…
Clarity and University of Melbourne receive Australian Research Council Grant funding for novel diagnostic imaging research Sydney, Australia 5 August 2015 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, has been co-awarded a prominent Australian Research Council (ARC) Linkage Grant with the University of Melbourne. The grant, valued at $365,000…
Sydney, Australia, 8 April 2015 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, has signed a licensing agreement with Baker IDI Heart and Diabetes Institute (Melbourne, Australia) to develop a diagnostic for the detection of rupture-prone plaque. The importance of detecting unstable, rupture-prone plaque, especially to prevent recurrent heart attacks,…
Professor Dale Bailey brings link to Translational Cancer Centre Sydney, Australia, 18 Dec 2014 – Sydney based biotech company Clarity Pharmaceuticals is pleased to announce that Professor Dale Bailey from PharmaScint, a specialist clinical trials imaging and analysis organization, has joined their expert scientific advisory group. In addition to being a Director of PharmScint, Professor…
Clarity Pharmaceuticals launched “Insight”, a quarterly newsletter focussed on the latest news in the imaging industry. The first issue explored Genentech’s anti-C-MET Phase III trial, and how imaging might have changed the outcome, and looked at how imaging has been used to successfully support the ZEPHIR trial. 1. Read Issue 1 here 2. Read Issue…
The latest article about Clarity Pharmaceuticals is in September’s Nature Biotechnology. Please contact us if you have any queries or interest in this area of radiopharmaceutical development. “Using positron emission tomography to visualize the distribution of a drug candidate in the entire body, Clarity Pharmaceuticals helps biopharmaceutical companies spend their money wisely on the most…
Clarity Pharmaceuticals was featured in an article in The Age about personalised medicine. “Dr Alan Taylor, a scientist and former investment banker, is now executive chairman of the Australian company Clarity Pharmaceuticals. Last month Clarity raised $1.1 million to further commercialise its personalised medicine companion diagnostic research. Clarity developed the technology to tag an antibody…